Needham & Company
-
PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
-
PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
PhaseBio Pharmaceuticals Inc. (PHAS) Prices 16M Share Common Offering at $3.50/Sh
-
PhaseBio Announces Pricing of Public Offering of Common Stock
-
PhaseBio Pharmaceuticals Inc. (PHAS) to Offer Common Stock
-
PhaseBio Announces Proposed Public Offering of Common Stock
-
PhaseBio Pharmaceuticals Inc. (PHAS) PT Raised to 'Street High' $19 at Needham & Company
-
Pre-Open Movers 06/18: (MGI) (PHAS) (BYND) Higher; (BHVN) (RMTI) (UBX) (more...)
-
PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
PhaseBio Pharmaceuticals Inc. (PHAS) PT Raised to $20 at Needham & Company
-
PhaseBio Pharmaceuticals Inc. (PHAS) Prices 3.6M Shares at $12
-
PhaseBio Announces Pricing of Public Offering of Common Stock
-
PhaseBio Announces Pricing of Public Offering of Common Stock
-
PhaseBio Pharmaceuticals Inc. (PHAS) Confirms 3M Share Offering of Common Stock
-
PhaseBio Announces Proposed Public Offering of Common Stock
-
PhaseBio Announces Proposed Public Offering of Common Stock
-
Pre-Open Stock Movers 04/09: (PHAS) (CERN) (AVYA) Higher; (ZGNX) (ZSAN) (DARE) Lower (more...)
-
Needham & Company Starts PhaseBio Pharmaceuticals Inc. (PHAS) at Buy
-
PhaseBio Pharmaceuticals (PHAS) IPO Opens Flat
-
PhaseBio Launches Roadshow for Initial Public Offering

